Cell line · CVCL_0588
Papers110
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 110
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer. | Cancer Drug Resist | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of HOX/PBX Dimers as a Potential Therapeutic Strategy in Breast Cancer Subtypes Including Triple Negative Breast Cancer. | Curr Issues Mol Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CDK8/19 inhibition prevents adaptive resistance to CDK4/6 inhibitors in vitro and in vivo. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. | Cell Rep Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of novel circular RNAs of the apoptosis-related BAX gene in breast cancer, by combining nanopore and next-generation sequencing. | Mol Genet Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TPP-45142-an Anti-HER2 T-cell Engager-Designed for Selective HER2-Low Cancer Immunotherapy. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Label-free imaging of intracellular structures in living mammalian cells via external apodization phase-contrast microscopy. | FEBS J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5p. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40654790 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein. | Breast Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0588/papers